Article
A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.
Blood - 25 Jan 2018
Yamaura Takeshi, Nakatani Toshiyuki, Uda Ken, Ogura Hayato, Shin Wigyon, Kurokawa Naoya, Saito Koichi, Fujikawa Norie, Date Tomomi, Takasaki Masaru, Terada Daisuke, Hirai Atsushi, Akashi Akimi, Chen Fangli, Adachi Yoshiya, Ishikawa Yuichi, Hayakawa Fumihiko, Hagiwara Shinji, Naoe Tomoki, Kiyoi Hitoshi
Abstract excerpt
An activating mutation of Fms-like tyrosine kinase 3 (FLT3) is the most frequent genetic alteration associated with poor prognosis in acute myeloid leukemia (AML). Although many FLT3 inhibitors have been clinically developed, no first-generation inhibitors have demonstrated clinical efficacy by m...
Topics
- Amides
- Animals
- Antineoplastic Agents
- Cell Line, Tumor
- Humans
- Leukemia, Myeloid, Acute
- Mice
- Molecular Docking Simulation
- Mutation
- Protein Kinase Inhibitors